Product information
From Health Canada
No match found
No other product was found with the same active ingredient group.
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Marketed
Current status date:
2013-04-17
Original market date: See footnote 1
2013-04-17
Product name:
JENTADUETO
DIN:
02403250
Product Monograph/Veterinary Labelling:
Date:
2021-03-05
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
BOEHRINGER INGELHEIM (CANADA) LTD LTEE
5180 South Service Road
Burlington
Ontario
Canada
L7L 5H4
Class:
Human
Dosage form(s):
Tablet
Route(s) of administration:
Oral
Number of active ingredient(s):
2
Schedule(s):
Prescription
American Hospital Formulary Service (AHFS): See footnote 3
68:20.05 , 68:20.04
Anatomical Therapeutic Chemical (ATC): See footnote 4
A10BD11 METFORMIN AND LINAGLIPTIN
Active ingredient group (AIG) number:See footnote5
0254133001
| Active ingredient(s) See footnote8 | Strength |
|---|---|
| METFORMIN HYDROCHLORIDE | 500 MG |
| LINAGLIPTIN | 2.5 MG |
Risk Management Plans See footnote 7
A Risk Management Plan (RMP) for this product was submitted.